[HTML][HTML] Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence
C Wagner, M Griesel, A Mikolajewska… - The Cochrane …, 2022 - ncbi.nlm.nih.gov
Background Systemic corticosteroids are used to treat people with COVID‐19 because they
counter hyper‐inflammation. Existing evidence syntheses suggest a slight benefit on …
counter hyper‐inflammation. Existing evidence syntheses suggest a slight benefit on …
Comparing the clinical characteristics and outcomes of COVID-19-associate pulmonary aspergillosis (CAPA): a systematic review and meta-analysis
Purpose Invasive pulmonary aspergillosis has been increasingly recognized in COVID-19
patients, termed COVID-19-associate pulmonary aspergillosis (CAPA). Our meta-analysis …
patients, termed COVID-19-associate pulmonary aspergillosis (CAPA). Our meta-analysis …
Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19 (April 2020)
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
[HTML][HTML] ESCMID COVID-19 living guidelines: drug treatment and clinical management
M Bartoletti, O Azap, A Barac, L Bussini… - Clinical microbiology …, 2022 - Elsevier
Abstract Scope In January 2021, the ESCMID Executive Committee decided to launch a new
initiative to develop ESCMID guidelines on several COVID-19-related issues, including …
initiative to develop ESCMID guidelines on several COVID-19-related issues, including …
Use of steroids in COVID-19 patients: A meta-analysis
Background Emerging reports have shown the benefits of steroids in hospitalized COVID-19
patients as life-saving drugs. However, the use of steroids in COVID-19 patients is confusing …
patients as life-saving drugs. However, the use of steroids in COVID-19 patients is confusing …
Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19 (September 2022)
There are many pharmacologic therapies that are being used or considered for treatment of
coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence …
coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence …
Systemic corticosteroids for the treatment of COVID‐19
Cochrane Haematology Group… - Cochrane Database …, 1996 - cochranelibrary.com
Background Systemic corticosteroids are used to treat people with COVID‐19 because they
counter hyper‐inflammation. Existing evidence syntheses suggest a slight benefit on …
counter hyper‐inflammation. Existing evidence syntheses suggest a slight benefit on …
The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis
J Wang, W Yang, P Chen, J Guo, R Liu, P Wen, K Li… - PloS one, 2021 - journals.plos.org
Objectives Coronavirus disease 2019 (COVID-19) remains a global challenge.
Corticosteroids constitute a group of anti-inflammatory and immunosuppressive drugs that …
Corticosteroids constitute a group of anti-inflammatory and immunosuppressive drugs that …
Low‐dose hydrocortisone in patients with COVID‐19 and severe hypoxia: the COVID STEROID randomised, placebo‐controlled trial
Background In the early phase of the pandemic, some guidelines recommended the use of
corticosteroids for critically ill patients with COVID‐19, whereas others recommended …
corticosteroids for critically ill patients with COVID‐19, whereas others recommended …
Immunomodulation as a potent COVID-19 pharmacotherapy: Past, present and future
In the first year of its appearance, the 2019 coronavirus disease (COVID-19) has affected
more than 150 million individuals and killed 3 million people worldwide. The pandemic has …
more than 150 million individuals and killed 3 million people worldwide. The pandemic has …